key: cord-0066637-axh2ub0g authors: Zoulikha, Makhloufi; Xiao, Qingqing; Boafo, George Frimpong; Sallam, Marwa A.; Chen, Zhongjian; He, Wei title: Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome date: 2021-08-12 journal: Acta Pharm Sin B DOI: 10.1016/j.apsb.2021.08.009 sha: b1d2acd62816f09af6b17084dada4fecdf62e4b0 doc_id: 66637 cord_uid: axh2ub0g The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the clinical translation of siRNA is hampered by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic. cells owing to several unfavorable physicochemical properties of naked siRNA. Thus, there have been significant efforts to design efficient vector systems to overcome the shortcomings in siRNA delivery and to develop stable siRNA formulations for pulmonary administration pushing forward towards the clinical availability of siRNA therapeutics for ALI/ARDS. In this review, we will first introduce the pathophysiological mechanisms of ALI/ARDS as the first step to determine the possible targets for siRNA. The potential of siRNA therapeutic as a novel approach to combat ALI/ARDS is then emphasized. Then, we highlight the privileges of the pulmonary route for the treatment of ALI/ARDS and we discuss the different intracellular and extracellular barriers that siRNA or siRNA carriers have to overcome to reach their targets. Finally, the different delivery vectors that can be applied for siRNA pulmonary delivery in ALI/ARD are presented. ALI/ARDS is divided into 3 phases: exudative, proliferative, and fibrotic. Initially, the injured lung goes by an acute/early or exudative phase characterized by damage of the alveolar barrier and pulmonary edema. Then, the exudative phase evolves into a proliferative or organizing phase after approximately 1 to 2 weeks to begin the process of lung repair, and finally, it may progress to an irreversible fibrotic phase in some patients 7,27-30 . This phase starts with the disruption of alveolar-capillary integrity by pulmonary or extrapulmonary injuries. Initially, resident alveolar macrophages (AMs) recognize nonendogenous pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharides (LPS) and lipoteichoic acid, or endogenous danger-associated molecular patterns (DAMPs), such as histones and high-mobility group box 1 (HMGB1), via pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). This leads to NF-κB-dependent polarization of AMs into M1like macrophages, that release pro-inflammatory mediators and chemokines contributing to the excessive recruitment of neutrophils and monocytic cells [30] [31] [32] [33] [34] [35] [36] [37] . The aggregation of neutrophils within the pulmonary vasculature can also result from the complement activation and release of C5a 7 . In the lung, activated neutrophils release numerous cytotoxic substances, including reactive oxygen species (ROS), various proinflammatory cytokines, granular enzymes, and J o u r n a l P r e -p r o o f neutrophil extracellular traps (NETs). In ALI/ARDS, AMs and neutrophils are the primary sources of proinflammatory cytokines. Consequently, the balance between proinflammatory (IL-1, IL-6, IL-8, IL-18, TNF-α, and TGF-β) and anti-inflammatory mediators (IL-10 and IL-13) is broken 13, 30, 35, 38 . This inflammatory dysfunction leads to the disruption of alveolar epithelium constituted of alveolar cells type (ATI), that cover the majority of the alveolar surface area playing a primary role in gas exchange and fluid reabsorption, as well as type II alveolar cells (ATII) playing a critical role in alveolar fluid clearance, the production of pulmonary surfactant, and the repopulation of the damaged ATI 10, 39 . The endothelial injury also contributes to the flooding of airspaces, but epithelium injury is more involved 39 . Eventually, the resultant increased alveolar-capillary permeability, surfactant dysfunction, and decreased alveolar fluid clearance lead to pulmonary edema, impaired gas exchange, and hypoxemia 10 . Furthermore, the irreversible damage of ATI and the subsequent replacement of the denuded space by the deposition of proteins, fibrin, and cellular debris, contribute to the formation of hyaline membranes ( Fig. 1A and B) 29 . Alveolar epithelial cell (EpiCs) death, either apoptotic or necrotic, is the most extreme form of alveolar barrier injury observed in ALI/ARDS, and one of the most important therapeutic targets for ALI/ARDS. Besides the inflammatory-induced epithelial injury, epithelial cell death can be directly caused by acid aspiration, hyperoxia, and physical forces 13, 39 . The disruption of the endothelial barrier leads to interstitial and alveolar immune cells infiltration and plasma extravasation, facilitated by the injury of alveolar epithelium increasing the pulmonary edema. Besides, the activation of endothelial cells (ECs) by stimuli such as hypoxia and inflammatory cytokines lead to their shift to prothrombotic, proinflammatory, and proadhesive phenotype promoting the procoagulant environment in ALI/ARDS (Fig. 2) 10, 40 . Overlapping with the exudative phase, the proliferative phase starts. In this phase, ATII cells proliferate and differentiate into ATI cells to replace injured and necrotic cells, leading to the reabsorption of alveolar edema and restoration of alveolar architecture and function 7, 15, 27 . Besides the epithelial integrity, endothelial integrity must also be restored, but this process is less well understood. Interestingly, it has been suggested that broncho-alveolar stem cells also have a role in this resolution 41 . Simultaneously, resolution of inflammation involves termination of pro-J o u r n a l P r e -p r o o f inflammatory signaling and clearance of apoptotic neutrophils 41 . AMs shift from M1 to M2 macrophages able to produce anti-inflammatory cytokines such as IL-4 and IL-13. This results in a decrease of proinflammatory cytokines production and removal of neutrophils, necrotic cells, and debris from the alveolar space ( Fig. 1C) 34, 42 . Also, it has been reported that T-regulatory lymphocytes may suppress cytokines production and neutrophil cell death contributing to the resolution of lung inflammation 41, 42 . Pulmonary fibrosis is a more frequent complication in ALI/ARDS of primary pulmonary origin 28 , that may start in parallel with the previous phases in some patients. It is marked by extensive basement membrane damage, persistent edema, loss of elastic tissue, and obliteration of alveolar spaces with a dense irregular matrix 27, 34, 43 . This is mainly due to the proliferation and accumulation of activated fibroblasts, secreting extracellular matrix proteins such as collagen, predominantly the fibrillar collagen type I, but also type III collagen 43 , resulting in the development of interstitial and intra-alveolar fibrosis that may slowly resolve or cause irreversible lung destruction. The observed fibroblast activation may be regulated by growth factors such as TGF-β, coagulation cascade proteins, and proinflammatory cytokines 44 . This phase does not happen in all ALI/ARDS patients but has been associated with mechanical, biochemical, and histological evidences of fibrosis with a doubling of lung collagen, progressive hypoxia, multiorgan failure, and increased mortality ( Fig. 1D) 27, 34, 44 . RNA interference (RNAi) is a natural cellular process that silences gene expression by promoting the degradation of mRNA 24 . RNAi mechanism was uncovered in Caenorhabditis elegans by Fire and Mello in 1998 45 , but it was until 2006 when it gained momentum as they won the Nobel Prize in Physiology or Medicine 46 . RNAi is a post-transcriptional gene regulation process wherein double-stranded endogenous or exogenous noncoding RNA molecules, including small interfering RNAs (siRNA), microRNAs (miRNAs), short RNAs (shRNAs), or piwi-interacting RNAs (piRNAs), induce silencing of homologous messenger RNA (mRNA) in a sequence-specific way 47 . Initially, the process starts by breaking down the double-stranded RNA (dsRNA) into smaller RNA duplexes, known as siRNA, by the enzyme Dicer. The resulting 21-23 nucleotide dsRNA, or the directly transfected synthetic siRNA, are then incorporated into the J o u r n a l P r e -p r o o f RNA-induced silencing complex (RISC). Subsequently, the endonuclease argonaute 2 (Ago-2) component of the RISC unwinds the duplex into two single-stranded RNAs, the "passenger or sense" that will be released, and the "guide or antisense" strand that will guide the complex RISC to the complementary target mRNA sequence. Finally, the complex cleaves the target mRNA, mediated by Ago-2, leading to inhibition of mRNA translation and the knockdown of the target gene [47] [48] [49] . Synthetic siRNAs are directly delivered to the cytosol, however, the plasmid-based shRNAs need to cross the cellular membrane to penetrate the nucleus where they are transcribed before being exported to the cytosol to be processed into active siRNAs 47 , and has therefore attracted less attention as a pharmaceutical agent in gene therapy 50 . Typically, siRNA can trigger specific gene silencing since the antisense strand only binds to mRNA that is perfectly complementary to it. By contrast, miRNA that has a stem-loop and whose biogenesis is initially started in the nucleus binds imperfectly to mRNA and can degrade multiple mRNA targets causing toxicity [21] [22] [23] [24] . Accordingly, RNAi therapy has unlimited choices of targets and it is possible to design effective RNAi drug targeting for any disease-promoting gene according to the mRNA sequence 25, 51 . siRNA is more favorable for therapeutic use over other gene therapies because it can be easily synthesized, does not require genome integration, and thereby avoids the gene therapy-related risks of mutation and teratogenicity 25 , with no problem of permanent modification since siRNA therapy can be stopped and controlled at any time and stage of treatment 52 . The delivery of siRNA is easier compared with shRNA plasmid or pDNA delivery since its site of action is the cytosol. Furthermore, siRNA has a small size, higher transfection efficacy, potency and specificity, fewer obstacles, and lower immune response, making them the best fit for RNAi therapeutics 22,23 . Since the discovery of the Nobel prize-winning mechanism of RNAi fifteen years ago 46 , it has become a promising drug target for treating a myriad of diseases, including genetic diseases, autoimmune and inflammatory diseases, cancer, and viral infection 53 . To date, three siRNAbased therapeutics are already in the pharmaceutical market. The first is ONPATTRO® (patisiran), a lipid nanoparticle administered intravenously once every 3 weeks, approved by the US Food and Drug Administration (FDA) in August 2018, to treat hereditary transthyretin amyloidosis (hATTR). The second is GIVLAARI™ (givosiran) approved in the USA in J o u r n a l P r e -p r o o f November 2019 to treat acute hepatic porphyria. The third is Oxlumo™ (lumasiran) approved in November 2020 by the EU and FDA to treat primary hyperoxaluria type 1. Both givosiran and lumasiran are administered subcutaneously as N-acetylgalactosamine (GalNAc) conjugates 54, 55 . Beyond the 3 siRNAs-based drugs already approved, there are another 7 in phase 3 trials. For instance, nedosiran is developed to treat primary hyperoxaluria, vutrisiran for the treatment of hATTR like patisiran, teprasiran for the prevention of acute kidney injury after transplant or cardiovascular surgery, fitusiran, for hemophilia A and B, tivanisiran to treat ocular pain and dry eye disease, and cosdosiran to treat nonarteritic anterior ischemic optic neuropathy. Also, siRNA therapy was expanded from orphan and rare diseases to more prevalent conditions, such as inclisiran for hypercholesterolemia 56 . Most of these drug candidates are GalNAc conjugates, except teprasiran, cosdosiran, and tivanisiran, which were not delivered with a carrier or conjugated to a targeting ligand. Notably, siRNAs have been previously reported to be an effective nucleic acid-based therapy in respiratory diseases [57] [58] [59] [60] , including ALI/ARDS, by targeting the essential inflammatory pathways involved in this disease 61, 62 . Much work has been done to find potential therapeutic targets of ALI/ARDS, such as those involved in epithelial-endothelial dysfunction, immune cell recruitment, or fibroblast activation; to reinforce lung defense mechanisms and enhance lung repair process 19, 63 . Nevertheless, these studies need to be accompanied by simultaneous research about the best delivery strategies of siRNA therapy of ALI/ARDS to achieve rapid successful outcomes. The delivery of drugs to the lung can be achieved directly via the pulmonary route or indirectly by systemic administration. However, nucleic acids can be degraded by serum nucleases in the bloodstream, hurdling the systemic delivery for siRNA 19 . In contrast, the local administration of siRNAs offers several important benefits over systemic delivery, such as minimized undesirable systemic effects, as well as reduced dose of siRNAs due to the high bioavailability at the target site and the lower lung nuclease activity improving siRNA stability and efficacy ( Fig. 3 ) 20, 23, 58, 62, 64 . Most importantly, the pulmonary route allows direct access to lung EpiCs, key target cells for gene knockdown in ALI/ARDS 21 . Although inhalation of siRNAs is clinically the most common and non-invasive method, the majority of in vivo studies were conducted intratracheally or intranasally due to their simplicity and ease of administration to animals compared to the inhalation formulations 21, 58, 65 . Clinically, intranasal instillations are easy to perform. However, the particles are vastly filtered out in the human nasal cavity. Similarly, intratracheal administration is relatively invasive and not suitable for human use 57 . It has been reported that the most appropriate method for pulmonary administration of siRNA-based therapeutics is inhalation using pressurized metered dose inhalers (pMDIs), requiring aerosolization of the drug by suspension or dissolution in a propellant 57 . The two other inhalation devices, nebulizers and dry powder inhalers (DPIs) are less common owing to the higher chance of siRNA degradation by the applied stress of nebulizers, and the difficulty to formulate siRNA-containing powders or preserving the integrity and bioactivity of siRNA, which hinders the use of DPIs 19 . However, the use of liquid formulations is not suitable for longterm storage. Accordingly, DPIs seem to be the more promising option because they are more stable, and have a lower risk of contamination extending their shelf-life 26,63,66-68 . Despite all the advantages of siRNA pulmonary delivery over systemic delivery, it still faces several barriers. This includes extracellular barriers that can be anatomical, physiological, metabolic, and immunological due to the inherent properties of the lung as well as intracellular barriers, related to the cellular uptake and endosomal escape 69, 70 , all with considering the disease pathological changes. Overcoming these barriers is indispensable to develop a successful inhalable siRNA against ALI/ARDS 61 . To reach its target, siRNA needs first to overcome the undermentioned extracellular barriers. presents an initial hurdle that siRNA must pass along to reach the deep lung area 57, 66 . Here, the site of deposition mainly depends on the size of particles. For deep penetration into the alveolar region, particles should have an optimal aerodynamic diameter between 1 and 5 μm, smaller enough to not deposit in the upper airways and larger enough for not being exhaled during normal breathing 62, 72 , with maximum deposition in alveoli region between 1 and 2 μm 73 . However, 100 nm particles have been stated to settle successfully into the alveolar space due to the Brownian diffusion mechanism 57, 62, 66, 73 . To avoid the exhalation of nanoparticles and improve their lung deposition, the "Trojan microparticles" or nanoparticles-in-microparticles, have been proposed to deliver them as dissociable microparticles having desired aerodynamic range (1-5 μmol/L in size) but can disassemble into nanoparticles upon lung deposition. Simultaneously, this strategy provides the aerodynamic behavior of microparticles and the ability of nanoparticles to avoid clearance 74, 75 . Accordantly, a previous study conducted in a rodent model using near-infrared (NIR) fluorescent NPs reported a negligible systemic absorption (less than 5 % after 1 h) of particles bigger than 100 nm after intratracheal administration. This study showed also that particles smaller than 34 nm were rapidly removed to the lymph and those smaller than 6 nm were quickly excreted in the urine 76 . These findings support the use of 100-200 nm as the optimal nanoscale for pulmonary route 74 . Typically, the extrapulmonary distribution of NPs is neglected in this nanoscale range. However, it may be enhanced by the loss of alveolar-capillary barrier integrity associated with ALI/ARDS 75 . After lung deposition, the next hurdle for siRNA pulmonary delivery to overcome is the clearance of particles. Clearance mechanisms depend on the site of deposition in the lung. The particles are mainly removed by the mucociliary clearance in the conducting airways and the AMs in the respiratory region 75, 77 . The continuous turnover of mucus, the mucociliary clearance driven by the physical action of the ciliated EpiCs, and the possible interactions (electrostatic, hydrophilic, hydrophobic) with particles, constitute a major pulmonary delivery barrier 72, 78 . The interaction of pulmonary delivered particles with mucus and their mucociliary clearance are both surface and particle-size-dependent 75 . It was found that particles larger than 500 nm were sterically immobilized. In contrast, 100-200 nm diameter particles rapidly penetrated the mucus of human respiratory systems 79 . Also, positively charged particles will be more trapped in the mucus rich in anionic mucin glycoproteins than the negatively charged particles. Yet, the commonly utilized siRNA delivery vehicles are J o u r n a l P r e -p r o o f polycationic which may hurdle their penetration to the mucus barrier, and therefore their therapeutic efficacy 80 . In contrast, neutral particles exhibited higher average transport rates 75 . The hydrophilic and neutral surfaces can be achieved by coating particles with hydrophilic and neutrally charged polymers, such as polyethylene glycol (PEG), or charge reversible peptides. In addition to the glycosylated regions, the mucin peptides may also trap hydrophobic particulates ( Fig. 4) 72, [78] [79] [80] [81] . Favorably, an enhanced mucoadhesion could prolong the lung retention time of pulmonary delivered particles, leading to an improved and pharmacokinetic profile 75 . The impaired mucociliary clearance in ALI/ARDS can further prolong this retention. Besides the respiratory mucus, the alveolar surface is covered by pulmonary surfactant (PS), a complex mixture of lipids and proteins 82 . PS can strongly interact with drugs hindering their effectiveness 19, 57 . Fortunately, this may not have a great impact on ALI/ARDS since surfactant production is disrupted. Formerly, PS has been considered as a siRNA delivery barrier to the respiratory target cells. Lately, a beneficial role of PS in local pulmonary siRNA delivery has been illustrated, hypothesizing that the lung surfactant proteins may act as an "endogenous" delivery vector 82 . On the other hand, the ALI/ARDS-increased alveolar fluid can hamper the drug molecules from reaching the epithelium. Moreover, the possible interaction of the cationic siRNA complexes with the anionic constituents of alveolar liquid, including phospholipids and proteins, especially in protein-rich edema fluid in ALI/ARDS constitutes another barrier that can hinder their diffusion. Also, the consolidated or collapsed alveoli further hinder the transducing of acutely injured lungs. Likewise, an associated cough can increase the removal of siRNA from the airways 19, 61 . Despite the lower metabolic capacity of the lung and its negligible nuclease activity, naked siRNA or siRNA carriers may undergo enzymatic degradation following pulmonary delivery, mediated by enzymes such as antitrypsin and proteases 61,75 . siRNA molecules deposited in the respiratory region are primarily cleared by AMs 77 , further accumulated in the airspace in ALI/ARDS, to be either degraded or removed to the lymphatic system 74 . It has been speculated that particles smaller than 150 nm can well escape AMs uptake 72 . Cationic particles can be bound to the anionic sialic acid present on the surface of AMs and thus preferentially phagocytosed compared with the negatively charged ones 75 . Similar to macrophages, neutrophils that are extensively recruited to J o u r n a l P r e -p r o o f the lungs in ALI/ARDS may contribute to siRNA clearance. Also, possible electrostatic interactions between siRNA delivery complexes and cytokines, chemokines, immunoglobulins, and complement components, remarkably increased in the ALI/ARDS alveolar space, can hinder their effectiveness 78 . Mechanical ventilation (MV) largely impacts the aerosolization efficiency and deposition within the respiratory tracts of the pulmonary delivered siRNA/siRNA carriers 83, 84 . Harmfully, the presence of heat and humidity in the ventilator circuit can reduce the efficiency of drug delivery 83 . In patients receiving mechanical ventilation, it is difficult to ensure that the aerosolized particles are efficiently delivered to distal airways 85 . It has been reported that the aerosol generated by nebulizers in mechanically ventilated patients was mostly deposited in proximal airways with a lung deposition lower than 20% of the nominal dose 84, 86 . Thus, inhalation devices and administration procedures have to be improved for patients under MV 84 . Positively, the time required to deliver a specified amount of drug to its target and the proportion of drugs delivered could be better managed by controlling the ventilator settings (tidal volume, airflow, inspiratory time/total duration of the breath) 83,85 . After overcoming the aforementioned extracellular barriers, siRNA has to bypass a set of intracellular barriers to reach RNAi machinery in the cytoplasm. The anionic cell membrane is another barrier to siRNA delivery. Naked siRNA does not easily cross the cell membrane due to its negative charge and high molecular weight 87 . Thus, effective delivery strategies may be used to facilitate siRNA cellular uptake. The major cell uptake pathway associated with the non-viral delivery of siRNA is endocytosis 72 . Generally, the cationic siRNA-carrier interacts with anionic proteoglycans and enters the cells by endocytosis 88 . Clathrin-dependent endocytosis is the best characterized and the most common route involved in the cellular uptake of siRNA during pulmonary delivery, particularly if the diameter is less than 200 nm 61, 66 . Particles under 150 nm can both avoid macrophage uptake and be efficiently endocytosed. Besides, caveolae-dependent endocytosis may also mediate siRNA cellular entry, especially for sizes greater than 500 nm 66 . After cellular entry, the entrapped siRNA/siRNA-carrier vesicles are transported in early endosomes that mature into late endosomes (pH 5-6), and then into J o u r n a l P r e -p r o o f lysosomes (pH ~4.5) containing nucleases and other degradative enzymes. Thereby, siRNAs must escape into the cytosol (pH ~7.4) at an early stage to avoid lysosomal degradation 66, 88 . The endosomal escape is the rate-limiting step for efficient siRNA delivery 88 . Several strategies have been investigated to promote the endosomal escape, including the incorporation of polymers such as polyethyleneimine (PEI) due to their high buffering capacity causing an increased osmolarity and endosome disruption, fusogenic lipids such DOPE (1,2-dioleoyl-L-α-glycero-3phosphatidylethanolamine) or pH-sensitive fusogenic peptides such as GALA (a repeat of glutamic acid-alanine-leucine-alanine, WEAALAEALAEALAEHLAEALAEALEALAA) owing to their ability to undergo conformational changes in low pH, causing a destabilization of endosomal membrane 66, 89 . Notably, it has been reported that even 0.1% endosomal escape in the cytosol of target cells may be enough for effective RNAi performance since siRNA can amplify itself within the cell 88 . For caveolae-mediated endocytosis, vectors are entrapped in nonacidic vesicles, transported to the Golgi or endoplasmic reticulum, and in that way escaping the lysosomal degradation 66,90 . Although the use of siRNAs seems to be a powerful approach against ALI/ARDS, its clinical application is still hurdled by many obstacles as discussed earlier. Similar to other nucleic acidbased therapeutics, this includes off-target effects, triggering of interferon responses, poor stability, and inefficient in vivo delivery, which have been the main challenge to applying siRNA-based therapeutics in humans 20, 53, 88 . The properties of suitable delivery systems for siRNAs as potential therapeutic agents include the ability to: (1) entrap siRNA into a stable particle, (2) effectively protect siRNA from enzymatic degradation, (3) avoid pulmonary extracellular barriers, (4) possess high transfection efficiency to facilitate its cellular uptake, (5) have good intracellular trafficking properties to promote the endosomal escape and the cytosolic release of siRNA. Also, an optimal siRNA delivery vector should be biodegradable, biocompatible, with negligible toxicity and immunogenicity, and should not cause inflammation. Also, it should be suitable for large-scale manufacturing (Fig. 5) 72, 88, 91 . Owing to the similarities between DNA and RNA, many vectors tested for DNA delivery have been explored for drug delivery of siRNA to the lung against ALI/ARDS (Table 2 ) 92-101 . Virus-based delivery vectors, such as adenoviruses, adeno-associated viruses, retroviruses, lentiviruses, were used to introduce genetic material into host cells after removing their virulence genes and inserting engineered genes into their genomes 102,103 . Adenovirus (AV), a non-enveloped double-stranded DNA (dsDNA) virus, was approved for clinical trials in 1990 as the first viral gene delivery vector 102 . Gendicine TM , which is an AVbased system loaded with mutated p53 gene, was approved by the CFDA in 2003 for treatment of head and neck squamous cell carcinoma as the first-ever gene therapy 104 . AV is widely used in lung-targeted gene therapy 105, 106 . However, AV-mediated gene delivery is limited by AVinduced immunological responses 105 , inflammation, and non-specificity of cell targeting 106 . Further, AV-mediated gene transfer is relatively inefficient in the absence of epithelial damage. However, this is not a limitation in the case of ALI/ARDS which is characterized by epithelial barrier dysfunction 105 . AAV is a small single-stranded DNA nonpathogenic parvovirus that is replication-defective and needs a helper virus to complete its lytic life cycle 107, 108 . AVVs are safer and less immunogenic compared to AV 105, 106 , which makes them an attractive candidate for gene delivery. However, they have lower transfection efficiency 102 . The AAV serotypes have different tissue tropisms due to different capsid proteins. The serotype AAV6 has been reported to be the most effective vector in infecting pulmonary epithelium 102, 105 . Interestingly, AVV capsid has been modified to improve both the safety and efficacy of these vectors for their application in gene therapy of several human diseases especially lung diseases 108 . Recently, Duncan et al. 109 highlighted the mucus-penetrating ability of AAV6 as a potential mechanism to achieve robust in vivo lung gene transfer and effective inhaled gene therapy. Successfully, AAV6 was used in a recent study to deliver miRNA-21-5p intending to inhibit apoptosis of ATII cells in hyperoxic acute lung injury (HALI) rats' model 109, 110 . Encouragingly, two AAV-based therapies have been approved by the FDA, luxturna (AAV2-based drug) indicated for rare eye disease and zolgensma, (AAV9based drug) for spinal muscular atrophy, in 2017 and 2019, respectively 107,111,112 . Retroviruses are enveloped RNA viruses characterized by their ability to reverse transcribing single-stranded RNA into dsDNA, before its insertion into the genome 21, 102, 113 . The nonspecificity, the insertional mutagenesis, and the risk of tumorigenesis are their major drawbacks 102, 105 . The most common type of retroviruses is lentivirus. Lentiviral vectors have been reported to have lower genotoxicity risk compared to other retroviral vectors 113 . Generally, despite the high transduction efficiency of viral vectors, their clinical application is limited by cytotoxicity, high immunogenicity, high potential of harmful insertional mutagenesis in the host genome, and even carcinogenesis 114 . Besides, viral delivery systems are more suitable for RNAi therapeutics that require transport into the nucleus such as miRNA and shRNA but not for siRNA that acts in the cytoplasm. Non-viral carriers have been developed to avoid the immune system stimulation associated with viral vectors 25 . Despite their relative safety and low-cost production 61 , these vectors generally do not possess the high level of tissue tropism and transfection efficiency of viral vectors 115 . The non-viral vectors applied for the pulmonary delivery of siRNA include various delivery systems, such as lipid-based, polymer-based, peptide-based delivery systems, and hybrid nanoparticles, etc. Commonly, lipid-based systems are the most investigated vectors for siRNA delivery. These include liposomes, stable nucleic acid lipid particles (SNALPs), solid lipid nanoparticles (SLNs), pH-responsive lipids, and exosomes (Table 3 Although PEI has an excellent gene condensation ability, high buffering capacity leading to great endosome escape activity, and high transfection efficiency 154 , it suffers from molecular weight-dependent cytotoxicity and nonbiodegradability hindering its application as an effective delivery system 155 PMs are nanocarriers (usually <100 nm) formed of a hydrophilic polymeric shell, such as PEG, and a hydrophobic core, such as PEI 164, 165 . Their biocompatibility, low toxicity, and relatively high stability make them attractive delivery systems 166 . Cationic micelle-forming block polymers can be used to trap negatively charged siRNAs in their core via electrostatic interaction 167 . Interestingly, PMs can be engineered to achieve active targeting and improved cellular uptake by their conjugation with specific targeting ligands or stimuli-responsive components 168 . However, they are limited by low loading efficiency and complexity in transport through the cell membrane 167 . Most recently, Hou J et al. 169 Comparatively, it has been reported that cationic phosphorus dendrimers have better delivery efficiency of siRNA than PAMAM dendrimers 173 . Further, these dendrimers themselves could possess a potent anti-inflammatory action 174 . A previous study conducted by Bohr et al. 98 inspected the potential of TNF-α siRNA cationic phosphorus dendrimers to modulate LPSinduced ALI both in vitro and in vivo. In their research, phosphorus third-generation (G3) dendrimers were functionalized with either cationic pyrrolidinium (DP) or morpholinium (DM) terminal groups. Results showed a strong binding between siRNA and both DP and DM dendrimers, with stronger binding for DP. This was attributed to the different pKa values between DP (8.1) and DM (7.1) resulting in higher ionization of DP in the pH of complexation. However, DP dendriplexes exhibited higher cytotoxicity against macrophages. This could be partly related to their higher surface charge. Similarly, DP dendriplexes showed better cellular uptake and improved in vitro silencing efficiency of TNF-α in LPS-activated macrophages than DM dendriplexes and/or non-complexed siRNA. In correlation with in vitro results, the nasal administration of DP dendriplexes in LPS-induced ALI murine model strongly inhibited TNF-α expression, much higher than DM dendriplexes and free siRNA 98 . Accordingly, in implementing dendriplexes for siRNA delivery, the dose should be carefully adjusted to compromise between achieving the highest efficacy and at the same time avoiding carrier-associated toxicity. Poly-L-lysine (PLL) is a well-known cationic polymer that has been widely studied as a nonviral gene delivery vector owing to its strong positive charge 74 Peptides are other possible carriers that can be applied for siRNA delivery because of their stability, low cytotoxicity and immunogenicity, biocompatibility, and biodegradabity 179, 180 . Peptides can be used alone or as an assistant component to other systems, such as fusogenic peptides used to bypass the endosomal entrapment barrier and cell-penetrating peptides (CPPs) used to facilitate the cellular entry 181 . Fusogenic peptides are short peptides that can promote endosomal release by increasing interactions with endosomal membrane 179 . GALA is a synthetic pHsensitive fusogenic peptide able to convert from a random coil structure at pH˃6 to an amphipathic a-helical structure able to insert into membranes and cause membrane leakage at pH˂6, promoting the endosomal escape 182, 183 . As abovementioned, GALA-modified MEND has been proposed as a siRNA carrier to take advantage of the dual role of GALA, enhancing the endosomal release, and targeting the lung endothelium 130 . CPPs are short chains of about 30 or fewer amino acids. Based on differences in physicochemical characters, CPPs can be classified into three classes: cationic, hydrophobic, and amphipathic [184] [185] [186] . Internalization of siRNA conjugated with CPPs can be mediated via endocytic or nonendocytic pathways depending on the particle size, peptide type, and siRNA loading method 187 . However, some CPPs have limitations due to nonspecificity and easy proteolysis 183 . Moreover, CPP-mediated delivery of siRNAs is majorly challenged by endosomal entrapment 188 . It has been reported that CPPs remain localized in the endosome and are further captured by lysosomes rather than undergoing endosomal escape 189 . 188, 191, 192 . Hence, covalent modification is most suitable for charge-neutral oligonucleotides than charged molecules such as siRNA 121 . Non-covalent CPP delivery of siRNA. The formation of nanoparticle complexes between anionic nucleic acids and CPPs is mainly driven by electrostatic and/or hydrophobic interactions 121, 190, 191 . Nevertheless, CPPs have poor encapsulating efficiency, and the nanoparticles formed are more heterogeneous and less defined than their CPP/siRNA conjugate counterparts 187, 188 . Further, CPPs have relatively low transfection efficiency requiring additional modifications to form efficient and stable CPP polyplexes because of their low molecular weight, weak electron charge density, inefficient gene complexation capability, limited capacity for endosomal escape, and rapid degradation under physiological conditions. Generally, CPPs are not used alone but as assistant components in lipoplexes and polymeric polyplexes 179 . Interestingly, CPP can be used for the co-delivery of genes and drugs 187 . For example, R3V6, a cationic amphiphilic peptide was used as a carrier for the delivery of the combinational therapy of sphingosine-1-phosphate lyase siRNA (siS1PLyase), reported to be involved in acute pulmonary inflammation, and recombinant HMGB1A, an antagonist of the pro-inflammatory cytokine HMGB1. The ternary NPs of siS1PLyase-HMGB1A-R3V6 has been designed to test the synergistic effect of siS1PLyase-HMGB1A against LPS-induced ALI model 99, 193 . Remarkably, the ternary NPs and siRNA/R3V6 nanocomplexes displayed higher stability compared with naked siRNA or siRNA/ PEI, confirming that R3V6 could protect siRNA from nucleases and proteases. The designed nanocomplex exhibited similar delivery efficiency into the lung EpiCs compared to siRNA-HMGB1A-PEI and siRNA-HMGB1A-Lipofectamine. Moreover, it was shown to be less toxic than both of them with higher anti-inflammatory potency against LPS-activated macrophages. Consistently, the intratracheal administration of siS1PLyase-HMGB1A-R3V6 NPs efficiently reduced the S1PLyase level, the inflammatory response, and apoptosis in lung tissue. These findings confirmed the advantages of the peptide R3V6 over other types of carriers in terms of toxicity and combined delivery of siS1PLyase and Hybrid lipid-polymer NPs combine both the natural biocompatibility and low immunogenicity of lipids, and the high binding affinity for RNA of polymeric nanocarriers 91, 194 . In this respect, Angelo et al. 195 Recently, Dormenval et al. 197 aimed to design physiochemically stable inhalable solid dosage forms for siRNA delivery suitable for large-scale production. Therefore, they prepared spray- nanocomposites. However, the administration of these nanocomposites to the naïve mice increased the inflammatory markers 101 . Most recently, the same group has demonstrated that the proteolipid coated siRNA-loaded nanogels can be freeze-dried and then reconstituted before nebulization for inhalation therapy without influencing their integrity or efficiency 199 . The field of siRNA therapy still attracts great interest due to its potential therapeutic to silence Both viral and non-viral vector systems have been designed or adapted to protect siRNA and deliver it to its cytosolic target after bypassing the different extracellular and intracellular barriers. Given the inherent immunogenicity of viral vectors, non-viral vectors are increasingly used to deliver nucleic acids. Although non-viral delivery systems are less efficient than viral vectors, they are less immunogenic, less expensive, and easier to produce in large amounts. Exosomes have also been proposed to deliver siRNA into the lung as nature's nano delivery system. However, exosome-mediated delivery is mainly hindered by purification techniques. Comparatively, liposomal delivery systems showed good transfection efficiency, polymer-based nanocarriers displayed sustained release profiles and higher cellular internalization potential, and peptide vectors exhibited enhanced endosomal escape. Interestingly, hybrid nanocarriers seem to be the best delivery system since it allows to combine the advantages of these different carriers J o u r n a l P r e -p r o o f Table 2 Respiratory siRNA-based preclinical studies against ALI/ARDS. Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) Lessons to learn from epidemiologic studies in ARDS The long-lasting effects of the acute respiratory distress syndrome Phenotypes and personalized medicine in the acute respiratory distress syndrome Acute respiratory distress syndrome Nunn's Applied Respiratory Physiology Acute respiratory distress syndrome. Principles of Pulmonary Medicine Stem cell derived exosomesbased therapy for acute lung injury and acute respiratory distress syndrome: a novel therapeutic strategy Acute respiratory distress syndrome: etiology, pathogenesis, and summary on management acute respiratory distress syndrome: therapeutics, pathobiology, and prognosis Current and J o u r n a l P r e -p r o o f evolving standards of care for patients with ARDS Acute respiratory distress syndrome (ARDS): definition, incidence, and outcome The basic science and molecular mechanisms of lung injury and acute respiratory distress syndrome Pediatric Acute Respiratory Distress Syndrome: a clinical guide Acute respiratory distress syndrome Corticosteroids in acute lung injury: the dilemma continues Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial Alternative and natural therapies for acute lung injury and acute respiratory distress syndrome RNAi therapeutic strategies for acute respiratory distress syndrome siRNA therapeutics: a clinical reality RNAi therapeutic platforms for lung diseases Therapeutic siRNA: state of the art Overcoming barriers for siRNA therapeutics: From bench to bedside siRNA versus miRNA as therapeutics for gene silencing Delivery systems for siRNA drug development in cancer therapy Pulmonary delivery of siRNA as a novel treatment for lung diseases Acute respiratory distress syndrome Kendig's Disorders of the Respiratory Tract in Children Acute respiratory distress syndrome Acute lung injury: A clinical and molecular review A review of inflammatory mechanism in airway diseases Acute lung injury: Disease modelling and the therapeutic potential of stem cells Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury The role of Macrophages in the Pathogenesis of ALI/ARDS Pathophysiology of acute respiratory distress syndrome Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases Intracellular codelivery of antiinflammatory drug and anti-miR 155 to treat inflammatory disease ROS signaling in the pathogenesis of Acute Lung Injury (ALI) and acute respiratory distress syndrome (ARDS) Acute respiratory distress syndrome Pathophysiology and management of acute respiratory distress syndrome in children Pathophysiology of acute respiratory distress syndrome Recent advances in dead cell clearance during acute lung injury and repair The acute respiratory distress syndrome: Fibrosis in J o u r n a l P r e -p r o o f the fast lane Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans The nobel prize in physiology or medicine RNA and CRISPR interferences: Past, present, and future perspectives RNA Interference: Application to Drug Discovery and Challenges to Pharmaceutical Development RNA Interference -A Hallmark of cellular function and gene manipulation PAMAM dendrimers as a delivery system for small interfering RNA Clinical advances of siRNA therapeutics siRNA delivery strategies: A comprehensive review of recent developments Journey of siRNA: Clinical developments and targeted delivery Givosiran: First approval Lumasiran: First approval The growth of siRNAbased therapeutics: Updated clinical studies Pulmonary delivery of therapeutic siRNA The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress Clinical translation of RNAi-based treatments for respiratory diseases Formulation of RNA interference-based drugs for pulmonary delivery: Challenges and opportunities Delivery of RNAi therapeutics to the airways -From bench to bedside SiRNA Delivery to the lung: What's new? Using two-fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation Future trends in nebulized therapies for pulmonary disease Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines Nanocarriers in effective pulmonary delivery of siRNA: Current approaches and challenges High siRNA loading powder for inhalation prepared by co-spray drying with human serum albumin Influence of physical properties of carrier on the performance of dry powder inhalers Delivery of siRNA therapeutics: Barriers and carriers Breaking down the barriers: siRNA delivery and endosome escape Development of human respiratory airway models: A review Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges Physicochemical properties of respiratory particles and formulations Nanotechnology approaches to pulmonary drug delivery: Targeted delivery of small molecule and gene-based therapeutics to the lung Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery Rapid translocation of nanoparticles from the lung airspaces to the body Inhalation Aerosols Aerosol Delivery of siRNA to the lungs. Part 1: Rationale for gene delivery systems Nanoparticle diffusion in respiratory mucus from humans without lung disease Pro-peptide-reinforced, mucuspenetrating pulmonary siRNA delivery mitigates cytokine storm in pneumonia Engineering drug delivery systems to overcome mucosal barriers for immunotherapy and vaccination Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy How should aerosols be delivered during invasive mechanical ventilation? Aerosol delivery during invasive mechanical ventilation: development of a preclinical ex vivo respiratory model for aerosol regional deposition Inhalation therapies in acute respiratory distress syndrome Aerosol delivery during invasive mechanical ventilation: A systematic review Magnetofection: Magic magnetic nanoparticles for efficient gene delivery siRNA based drug design , quality , delivery and clinical translation Breaking down the barriers: siRNA delivery and endosome escape Nanocarrier-mediated cytosolic delivery of biopharmaceuticals An Overview of various carriers for siRNA delivery Blockade of endothelial, but not epithelial, cell expression of PD-L1 following severe shock attenuates the development of indirect acute lung injury in mice Gene silencing of receptorinteracting protein 2 protects against cigarette smoke-induced acute lung injury Exosome-mediated small RNA delivery: a novel therapeutic approach for inflammatory lung responses c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury Treatment of acute lung injury and early-and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model Antiinflammatory effect of anti-TNF-α siRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury model Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury Fluorinated α-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy Gene therapy leaves a vicious cycle The interface of drug delivery and regenerative medicine The First approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic Clinical Review: gene-based therapies for ALI/ARDS: Where are we now? Gene therapy for ALI/ARDS Development and deployment of gene therapies: An ADA-SCID case study Capsid modifications for targeting and improving the efficacy of AAV vectors An adenoassociated viral vector capable of penetrating the mucus barrier to inhaled gene therapy miR-21-5p ameliorates hyperoxic acute lung injury and decreases apoptosis of AEC II cells via PTEN/AKT signaling in rats First AAV gene therapy poised for landmark approval Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here Lentiviral vectors for the treatment and prevention of cystic fibrosis lung disease Immune responses to viral gene therapy vectors Polymeric vectors for strategic delivery of nucleic acids Liposomal siRNA nanocarriers for cancer therapy Recent advances in siRNA delivery mediated by lipidbased nanoparticles Toxicological exploration of peptide-based cationic liposomes in siRNA delivery Targeted systemic delivery of therapeutic siRNA Biological drug and drug delivery Internalization mechanisms of cell-penetrating peptides SiRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes Lipid nanoparticles as non-viral vectors for siRNA delivery: Concepts and applications Cationic liposomes carrying siRNA: Impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape Drug Targeting and Stimuli Sensitive Drug Delivery Systems Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures Aerosolizable siRNAencapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary delivery Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes Multifunctional envelope-type nano device: Evolution from nonselective to active targeting system Lungendothelium-targeted nanoparticles based on a pH-sensitive Lipid and the GALA peptide enable robust gene silencing and the regression of metastatic lung cancer Designer exosomes: a new platform for biotechnology therapeutics Exosomes as novel bio-carriers for gene and drug delivery Advances in exosome-based drug delivery and tumor targeting: J o u r n a l P r e -p r o o f from tissue distribution to intracellular fate Exosomes as drug delivery systems: a brief overview and progress update Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges Recent advancements in the use of exosomes as drug delivery systems Innovative nonviral vectors for small-interfering RNA delivery and therapy Cell transfection Progress in systemic co-delivery of microRNAs and chemotherapeutics for cancer treatment by using lipid-based nanoparticles Optimized combination of cationic lipids and neutral helper lipids in cationic liposomes for siRNA delivery into the lung by intravenous injection of siRNA lipoplexes Aerosol delivery of siRNA to the lungs. Part 2: Nanocarrier-based delivery systems Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes Validating the use of short interfering RNA as a novel technique for cell-specific target gene knockdown in lung ischemia-reperfusion injury Trends in the biological functions and medical applications of extracellular vesicles and analogues Exosomes from iPSCs delivering siRNA attenuate intracellular adhesion molecule-1 expression and neutrophils adhesion in pulmonary microvascular endothelial cells Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications A summary on non-viral systems for gene delivery based on natural and synthetic polymers Polymeric siRNA gene delivery-transfection efficiency versus cytotoxicity Polymeric vehicles for nucleic acid delivery Dendrimers in gene delivery Advanced polymers for nonviral gene delivery Theory and limitations to gene therapy Polymer-based nanocarriers for therapeutic nucleic acids delivery Recent advances in polymeric drug delivery systems SiRNA conjugated nanoparticles-a next generation strategy to treat lung cancer Gene therapy potential applications of nanotechnology Targeting promoter-associated noncoding RNA in vivo Dexamethasone-conjugated polyethylenimine/MIF siRNA complex regulation of particulate matter-induced airway inflammation Combining fluorination and bioreducibility for Improved siRNA polyplex delivery Vaporized perfluorocarbon inhalation attenuates primary blast lung injury in canines by inhibiting mitogen-activated protein kinase/nuclear factor-κB activation and inducing nuclear factor, erythroid 2 like 2 pathway Sustained improvement of gas exchange and lung mechanics by vaporized perfluorocarbon inhalation in piglet acute lung injury model Therapeutic effect of intravenous infusion of perfluorocarbon emulsion on LPS-induced acute lung injury in rats PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery Innovation in nanomedicine and engineered nanomaterials for therapeutic purposes Recent advances in development of nano drug delivery Polymer-based nanomaterials for drug-delivery carriers Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review Delivery strategies of amphotericin B for invasive fungal infections Co-delivery of siPTPN13 and siNOX4 via (myo)-fibroblasttargeting polymeric micelles for idiopathic pulmonary fibrosis therapy Targeted dual small interfering ribonucleic acid delivery via non-viral polymeric vectors for pulmonary fibrosis therapy Polymers in drug delivery: an update Inhalable siRNAloaded nano-embedded microparticles engineered using microfluidics and spray drying Phosphorus dendrimers as powerful nanoplatforms for drug delivery, as fluorescent probes and for liposome interaction studies: a concise overview In vivo therapeutic applications of phosphorus dendrimers: state of the art Poly(D,L-lactide-co-glycolide)-based nanoparticles Drug delivery mediated by confined nanosystems: structure-activity relations and factors responsible for the efficacy of formulations Lipid/polymerbased nanocomplexes in nucleic acid delivery as cancer vaccines Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation Peptide-based gene delivery vectors Shear-responsive peptide/siRNA complexes as lung-targeting gene vectors Peptide photocaging: a brief account of the chemistry and biological applications Versatility of cell-penetrating peptides for intracellular delivery of siRNA Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems Cell penetrating peptides, novel vectors for gene therapy Nanoparticles modified with cell-penetrating peptides: conjugation mechanisms, physicochemical properties, and application in cancer diagnosis and therapy Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application Cell penetrating peptides: a versatile vector for codelivery of drug and genes in cancer Peptides for nucleic acid delivery Endosomal escape tendency of drug delivery systems to mediate cytosolic delivery of therapeutics Cell-penetrating peptides to enhance delivery of oligonucleotide-based therapeutics A retroinverso cell-penetrating peptide for siRNA delivery Advances in oligonucleotide drug delivery Peptide-based nanoassemblies in gene therapy and diagnosis: paving the way for clinical application Paliperidone-loaded nanolipomer system for sustained delivery and enhanced intestinal permeation: Superiority to polymeric and solid lipid nanoparticles Hybrid lipid/polymer nanoparticles for pulmonary delivery of siRNA: development and fate upon in vitro deposition on the human epithelial airway barrier Naringenin-loaded dipalmitoylphosphatidylcholine phytosome dry powders for inhaled treatment of acute lung injury Identification of factors of importance for spray drying of small interfering RNA-loaded lipidoid-polymer hybrid nanoparticles for inhalation Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy This study was supported by the National Natural Science CS, cigarette smoke; CXCR4, C-X-C motif chemokine receptor type 4; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; eggPG, L-αphosphatidylglycerol; HMGB1A, high-mobility group box 1A; LPS, lipopolysaccharides; Myd88, myeloid differentiation primary response 88; PAI-1, plasminogen activator inhibitor-1; PAMAM, polyamidoamine; PD-L1, programmed death ligand-1; PEI, polyethyleneimine; PFC, perfluorocarbon; Rip2, receptor-interacting protein 2; siS1PLyase, sphingosine-1-phosphate lyase siRNA; TNF-α, tumor necrosis factor-α.